Reuters logo
BRIEF-Concert Pharmaceuticals says announces CTP-543 positive top-line Phase 1 results
December 14, 2016 / 12:42 PM / 9 months ago

BRIEF-Concert Pharmaceuticals says announces CTP-543 positive top-line Phase 1 results

Dec 14 (Reuters) - Concert Pharmaceuticals Inc

* Concert pharmaceuticals - CTP-543 well-tolerated across all dose groups in study & there were no serious adverse events in subjects who received CTP-543

* Concert Pharmaceuticals announces CTP-543 positive top-line phase 1 results

* Phase 2A clinical trial for CTP-543 is expected to begin in Q1 of 2017

* Concert Pharmaceuticals Inc - intends to present phase 1 findings at a medical conference in 2017

* Trial is expected to commence in Q1 of next year and topline primary outcome data is expected by end of 2017

* Concert Pharmaceuticals-Phase 2 A trial for CTP-543 is expected to commence in Q1 of next year, topline primary outcome data is expected by end of 2017 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below